Hypertrophic cardiomyopathy: investigational drugs inhibiting myosin and upcoming agents

References

• Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet (London, England). 2004 Jun 5;363(9424):1881–1891. 10.1016/S0140-6736(04)16358-7
   PubMed Web of Science ®Google Scholar
• Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA study. Coronary artery risk development in (young) adults. Circulation. 1995 Aug 15;92(4):785–789. doi: 10.1161/01.CIR.92.4.785
   PubMed Web of Science ®Google Scholar
• Varnava AM, Elliott PM, Baboonian C, et al. Hypertrophic cardiomyopathy: histopathological features of sudden death in cardiac troponin T disease. Circulation. 2001 Sep 18;104(12):1380–1384. doi: 10.1161/hc3701.095952
   PubMed Web of Science ®Google Scholar
• Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, Pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. 2017 Sep 15;121(7):749–770. doi: 10.1161/CIRCRESAHA.117.311059
   PubMed Web of Science ®Google Scholar
• Bonaventura J, Polakova E, Vejtasova V, et al. Genetic testing in patients with hypertrophic cardiomyopathy. Int J Mol Sci. 2021 Sep 27;22(19):10401. doi: 10.3390/ijms221910401
   PubMed Web of Science ®Google Scholar
• Kogut J, Popjes ED. Hypertrophic cardiomyopathy 2020. Curr Cardiol Rep. 2020 Oct 06;22(11):154.
   PubMed Web of Science ®Google Scholar
• Maron BJ, Desai MY, Nishimura RA, et al. Management of hypertrophic cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2022 Feb 1;79(4):390–414. doi: 10.1016/j.jacc.2021.11.021
   PubMed Web of Science ®Google Scholar
• Mentias A, Smedira NG, Krishnaswamy A, et al. Survival after septal reduction in patients >65 years old with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2023 Jan 17;81(2):105–115. doi: 10.1016/j.jacc.2022.10.027
   PubMed Web of Science ®Google Scholar
• Green EM, Wakimoto H, Anderson RL, et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science. 2016 Feb 5;351(6273):617–621. doi: 10.1126/science.aad3456
   PubMed Web of Science ®Google Scholar
• Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England). 2020 Sep 12;396(10253):759–769. doi: 10.1016/S0140-6736(20)31792-X
   PubMed Web of Science ®Google Scholar
• Desai MY, Owens AT, Geske JB, et al. Dose-blinded myosin inhibition in patients with obstructive HCM referred for septal reduction therapy: outcomes through 32-weeks. Circulation. 2022 Nov 6;147:850–863. doi: 10.1161/CIRCULATIONAHA.122.062534
   PubMed Web of Science ®Google Scholar
• Desai MY, Owens A, Geske JB, et al. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy. J Am Coll Cardiol. 2022 Jul 12;80(2):95–108. doi: 10.1016/j.jacc.2022.04.048
   PubMed Web of Science ®Google Scholar
• Masri A, Olivotto I. Cardiac myosin inhibitors as a novel treatment option for obstructive hypertrophic cardiomyopathy: addressing the core of the matter. J Am Heart Assoc. 2022;11(9):e024656. doi: 10.1161/JAHA.121.024656
   PubMed Web of Science ®Google Scholar
• Maron MS, Masri A, Choudhury L, et al. Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2023 Jan 3;81(1):34–45. doi: 10.1016/j.jacc.2022.10.020
   PubMed Web of Science ®Google Scholar
• Chuang C, Collibee S, Ashcraft L, et al. Discovery of aficamten (CK-274), a Next-Generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy. J Med Chem. 2021 Oct 14;64(19):14142–14152. doi: 10.1021/acs.jmedchem.1c01290
   PubMed Web of Science ®Google Scholar
• MyoKardia IawosoB-MS. Full prescribing information: Camzyos. FDA medication Guide MyoKardia, Inc. A wholly owned subsidiary of Bristol-Myers Squibb 2022. p. 1–27.
   Google Scholar
• PM BJ. In: StatPearls [internet]. [Updated 2023 Jan 17] (Treasure Island (FL): StatPearls Publishing; Available from: https://www.ncbi.nlm.nih.gov/books/NBK582152/).
   Google Scholar
• Liew AC, Vassiliou VS, Cooper R, et al. Hypertrophic cardiomyopathy—past, present and future. J Clin Med. 2017 Dec 12;6(12):118. doi: 10.3390/jcm6120118
   PubMed Web of Science ®Google Scholar
• Marian AJ. Molecular genetic basis of hypertrophic cardiomyopathy. Circ Res. 2021;128(10):1533–1553. doi: 10.1161/CIRCRESAHA.121.318346
   PubMed Web of Science ®Google Scholar
• Rader F, Choudhury L, Saberi S, et al. LONG-TERM SAFETY of MAVACAMTEN in PATIENTS with OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: INTERIM RESULTS of the MAVA-LONG TERM EXTENSION (LTE) STUDY. J Am Coll Cardiol. 2021;77(18_Supplement_1):532–532. doi: 10.1016/S0735-1097(21)01891-X
   Google Scholar
• Spoladore R, Maron MS, D’Amato R, et al. Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence. Eur Heart J. 2012 Jul;33(14):1724–1733. doi: 10.1093/eurheartj/ehs150
   PubMed Web of Science ®Google Scholar
• Dainis A, Zaleta-Rivera K, Ribeiro A, et al. Silencing of MYH7 ameliorates disease phenotypes in human iPSC-cardiomyocytes. Physiol Genomics. 2020 Jul 1;52(7):293–303. doi: 10.1152/physiolgenomics.00021.2020
   PubMed Web of Science ®Google Scholar
• Reichart D, Newby GA, Wakimoto H, et al. Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice. Nat Med. 2023 Feb;29(2):412–421. doi: 10.1038/s41591-022-02190-7
   PubMed Web of Science ®Google Scholar
• Chai AC, Cui M, Chemello F, et al. Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice. Nature Med. 2023 Feb 01;29(2):401–411. doi: 10.1038/s41591-022-02176-5
   PubMedGoogle Scholar
• Strong A. CRISPR gene-editing therapies for hypertrophic cardiomyopathy. Nature Med. 2023 Feb 01;29(2):305–306.
   PubMedGoogle Scholar
• Reichart D, Newby GA, Wakimoto H, et al. Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice. Nature Med. 2023 Feb 01;29(2):412–421. doi: 10.1038/s41591-022-02190-7
   PubMed Web of Science ®Google Scholar